Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists

  title={Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists},
  author={John T. Reilly},
  pages={1 - 10}
  • J. Reilly
  • Published 1 February 2009
  • Medicine
  • Hematology
Abstract Two hundred and fifty hematologists and oncologists (50 each from France, Germany, Italy, Spain and the United Kingdom) participated in this survey to assess the current management of essential thrombocythemia (ET), with particular reference to the use of anagrelide. Data were collected between October 9 and November 2, 2006 on 2000 patients with ET. Thirty-eight per cent of patients had been tested for the Janus kinase 2 (JAK2) mutation (JAK2V617F), of whom 54% tested positive… 
Current treatment practices for essential thrombocythemia: survey results from European hematologists/oncologists
Insight was gained into physicians' criteria for treatment initiation and reasons for switching from one therapy option to another for essential thrombocythemia (ET), andfficacy was the main factor cited for switching therapies.
[Diagnosis and therapy for patients with essential thrombocythemia. Guidelines of Croatian Cooperative Group for hematologic disorders--KROHEM].
Therapy is based on risk factors for ET, number of platelets, patient's age, and the risk levels for thrombosis and bleeding, and Alpha-interferon is recommended for pregnant women with ET and high platelet counts.
Defining targets in myeloproliferative disorders: reflecting on what is important
Recent revisions to the World Health Organization diagnostic criteria for the chronic MPDs 1 have implications not only for the diagnosis of patients, but also for the management of their disease and the continuing assessment of their progress.
Serum chitotriosidase: a circulating biomarker in polycythemia vera
Serum chitotriosidase activity (CHIT1) is a biomarker of macrophage activation with an important role in inflammation-induced tissue remodeling and fibrosis and might be considered as a circulating biomarker in PV.
Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene
The combined use of metformin with chemotherapy is effective in patients with elevated levels of ABCB1 gene expression, and there is a benefit to adding met formin in the group of patients with high ABCB 1 gene expression.
Management of chronic lymphocytic leukemia in elderly patients
In elderly patients who need treatment for CLL, evaluation of disease-specific risk factors should be accompanied by measurement of fitness status and co-morbidities so that a treatment option can be selected that best fits the individual patient's goals of therapy.
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment
Compared the gene expression profiling of bone marrow (BM) CD34+/lin- cells from CP-CML patients at diagnosis and after 12 months of nilotinib treatment by microarray, GEP data demonstrated the deregulation of genes involved in the JAK-STAT signaling pathway and the up-regulation of cell cycle, proliferation and differentiation via MAPK and PI3K-AKT signaling pathways at diagnosis.


[Anagrelide in the treatment of thrombocythemia essential (ET)].
Anagrelide proved to be an effective drug for of ET patients refractory to prior treatment with hydroxyurea and reduced platelet count in all patients.
Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany
Preliminary evidence suggests that anagrelide mediated platelet count reduction also prevents recurrence of thromboembolic complications and has the potential to become the first‐line platelet‐lowering treatment in myeloproliferative disorders with high platelet counts.
A long-term study of young patients with essential thrombocythemia treated with anagrelide.
Anagrelide appears suitable for controlling thrombocytosis in ET patients over the long-term, and this drug may be used in patients younger than 60 years, with the exclusion of women of child-bearing potential and subjects aged 40-60 years with a history of majorThrombotic events.
[Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
Ten-year experience in the treatment of ET with anagrelide (A), a non mutagenic drug that inhibits megakaryocyte maturation, effective in reducing platelet counts and preventing mayor thrombotic events is reported.
Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results.
It is said that Anagrelide is an effective drug in the treatment of patients with E.T., but its side effects must be seriously considered.
Long-term use of anagrelide in young patients with essential thrombocythemia.
It is concluded that long-term treatment of ET with anagrelide is associated with decreased reporting of initial side effects and the development of mild-to-moderate anemia, and complete normalization of platelet counts may be needed to minimize residual thrombohemorrhagic risk during therapy.
Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.
There was a high risk of progression to myelofibrosis in the patients treated by HU, which was significantly higher than with Pi, and the risk of leukemia was approximately 10% at the 13th year, with no significant difference between the two arms.
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
Side effects and toxic discontinuation rates were higher than in previous studies, probably because this is the first long-term prospective study of the feasibility and toxicity of anagrelide treatment.
Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
Anagrelide is safe and effective in reducing the platelet counts, but a high proportion of the patients discontinue treatment because of the adverse effects of the drug, which supports the hypothesis that aggressive control of thrombocytosis to a platelet count <400 x 10(9)/l might reduce the number ofThrombohaemorrhagic events.